Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Buys 150,000 Shares

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall purchased 150,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was acquired at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the transaction, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This represents a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Immunome Trading Down 6.4 %

Shares of NASDAQ IMNM traded down $0.71 during mid-day trading on Monday, hitting $10.32. The company had a trading volume of 1,122,794 shares, compared to its average volume of 1,001,049. Immunome, Inc. has a 1 year low of $8.97 and a 1 year high of $30.96. The company has a market capitalization of $644.17 million, a price-to-earnings ratio of -1.27 and a beta of 1.90. The stock’s 50-day moving average price is $11.34 and its 200-day moving average price is $12.68.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Stoneridge Investment Partners LLC purchased a new position in shares of Immunome during the fourth quarter valued at approximately $123,000. AQR Capital Management LLC increased its position in shares of Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after purchasing an additional 4,129 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Immunome during the 3rd quarter valued at $219,000. Three Bridge Wealth Advisors LLC purchased a new position in shares of Immunome during the 4th quarter valued at about $293,000. Finally, JPMorgan Chase & Co. boosted its holdings in Immunome by 6.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock worth $359,000 after buying an additional 1,520 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on IMNM shares. Stephens initiated coverage on shares of Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Monday, January 13th. Finally, Piper Sandler lowered their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $28.60.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.